|Articles|April 5, 2021

Ajinomoto expands its manufacturing arrangement with AstraZeneca

Agreement will now include fill-finish services at San Diego facility

Ajinomoto Bio-Pharma Services, a contract development and manufacturing organization (CDMO), and AstraZeneca are expanding their manufacturing agreement to include drug product manufacturing.

This agreement expands the extent of Aji Bio-Pharma's service offerings to AstraZeneca to also feature aseptic fill-finish services at its San Diego, CA, facility, along with small molecule manufacturing services proceeding in Belgium.

"We are excited to expand our manufacturing agreement with AstraZeneca and to support them with additional service offerings," said Magnus Busch, Ajinomoto’s global account manager. "Our San Diego team is proud to join our Belgium colleagues in support of AstraZeneca. This expanded agreement builds on our commitment to be a leading, trusted, innovative partner to our clients."

Aji Bio-Pharma has sites in India and Japan as well.


Related to this article

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS). | © Tada Images - stock.adobe.com 521699065
In this week’s Pharma Pulse, the FDA launches a program that lets companies share its approval packages with foreign regulators, UPS agrees to acquire Australia and New Zealand health care courier Smartways Logistics and Cognizant introduces an AI-enabled patient hub offering.